SCHEMBL4467147

SCHEMBL4467147

O=C(O)N(CCc1ccc(Br)cc1)Cc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RCE1 Q9Y256 1/20 0.52
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
HDAC1 Q13547 3/20 0.52
HDAC6 Q9UBN7 3/20 0.52
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
L3MBTL1 Q9Y468 2/20 0.50
ALDH1A1 P00352 1/20 0.50
LMNA P02545 1/20 0.50
MAPT P10636 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
CA12 O43570 3/20 0.49
CA1 P00915 3/20 0.49
CA2 P00918 3/20 0.49
CA4 P22748 2/20 0.48
PLAAT3 P53816 1/20 0.48
PLAAT5 Q96KN8 1/20 0.48
PLAAT2 Q9NWW9 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1901574 1.00 RCE1 (0.52) RCE1MEN1KMT2AHDAC1HDAC6
SCHEMBL7228409 0.89 MEN1 (0.61) RCE1MEN1KMT2AHDAC1HDAC6
SCHEMBL10399486 0.89 RCE1 (0.52) RCE1MEN1KMT2AHDAC1HDAC6
SCHEMBL2315734 0.87 RCE1 (0.52) RCE1MEN1KMT2AHDAC1HDAC6
SCHEMBL2310278 0.85 RCE1 (0.54) RCE1MEN1KMT2AHDAC1HDAC6
SCHEMBL16507094 0.83 LPAR1 (0.60) RCE1HDAC1HDAC6LPAR1LPAR5
SCHEMBL13708399 0.82 HDAC1 (0.52) RCE1MEN1KMT2AHDAC1HDAC6
SCHEMBL5933377 0.82 TDP1 (0.66) RCE1MEN1KMT2AHDAC1HDAC6
SCHEMBL29154704 0.81 TDP1 (0.49) RCE1MEN1KMT2AHDAC1HDAC6
SCHEMBL26665230 0.81 RCE1 (0.50) RCE1MEN1KMT2AHDAC1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7629366-B2 Aminoalcohol derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2009-12-08 US disclosed
US-20060100252-A1 Aminoalcohol derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2006-05-11 US disclosed
US-7037938-B2 Aminoalcohol derivatives ASTELLAS PHARMA INC. (JP) 2006-05-02 US disclosed
EP-1546086-A2 AMINOALCOHOL DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-06-29 EP disclosed
WO-2004002939-A2 AMINOALCOHOL DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-01-08 WO disclosed
US-20040006143-A1 For therapy of urinary incontinence FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100252-A1 Aminoalcohol derivatives H1-0, CHRM2, CHRM1 RCE1 3028/4885MEN1 4134/4885KMT2A 1218/4885
US-20040006143-A1 For therapy of urinary incontinence H1-0, HRH2, H1-2 RCE1 2204/4885MEN1 4292/4885KMT2A 364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.